$Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma$

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma

Iberdomide is a potent cereblon E3 ligase modulator (CELMoD agent) with promising efficacy and safety as a monotherapy or in combination with other therapies in patients with relapsed/refractory multiple myeloma (RRMM). Using a custom mass cytometry panel designed for large-scale immunophenotyping o...

Full description

Bibliographic Details
Main Authors:	Van Oekelen, O, Amatangelo, M, Guo, M, Upadhyaya, B, Cribbs, AP, Kelly, G, Patel, M, Kim-Schulze, S, Flynt, E, Lagana, A, Gooding, S, Merad, M, Jagganath, S, Pierceall, WE, Oppermann, U, Thakurta, A, Parekh, S
Format:	Journal article
Language:	English
Published:	Cell Press 2024

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma

Similar Items